Interleukin-2 [IL-2]

DRUG2 trials

Sponsors

Cambridge University Hospitals NHS Foundation Trust

Conditions

Acute Coronary SyndromesCarotid Artery PlaqueCarotid AtherosclerosisTIA

Phase 2

Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes - IVORY

CompletedNCT04241601

Cambridge University Hospitals NHS Foundation TrustAcute Coronary Syndromes

Start: 2020-08-05End: 2023-01-25Updated: 2024-06-10

Unknown Phase

The Effect of Low-dose Interleukin-2 on the Immune Landscape of Human Atherosclerotic Plaques at Single Cell Resolution.

Active, not recruitingNCT05975554

Cambridge University Hospitals NHS Foundation TrustCarotid Artery Plaque, Carotid Atherosclerosis, TIA

Start: 2023-08-26End: 2025-09-01Target: 30Updated: 2025-05-30

Related Papers

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial.

2026-01-081 citations

Low-dose <i>i</i> nterleukin 2 for the reduction of <i>v</i> ascular inflammati <i>o</i> n in acute corona <i>ry</i> syndromes (IVORY): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase II clinical trial

BMJ Open2022-10-0138 citations